ZA974366B - Potassium, sodium and tris oxaprozin salt pharmaceutical formulations. - Google Patents

Potassium, sodium and tris oxaprozin salt pharmaceutical formulations.

Info

Publication number: ZA974366B
Authority: ZA; South Africa
Prior art keywords: sodium; potassium; pharmaceutical formulations; salt pharmaceutical; tris
Prior art date: 1996-05-20

Application number

ZA9704366A

Other languages

English (en)

Inventor

Mark E Adams

Subhash Desai

Aziz Karim

Kalidas Paul

Douglas J Schaaf

David J Zold

Original Assignee

Searle & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-20

Filing date

1997-05-20

Publication date

1998-05-20

1997-05-20 Application filed by Searle & Co filed Critical Searle & Co

1998-05-20 Publication of ZA974366B publication Critical patent/ZA974366B/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title abstract 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title abstract 2
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical class O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 title abstract 2
229910052700 potassium Inorganic materials 0.000 title abstract 2
239000011591 potassium Substances 0.000 title abstract 2
229910052708 sodium Inorganic materials 0.000 title abstract 2
239000011734 sodium Substances 0.000 title abstract 2
239000007983 Tris buffer Substances 0.000 title 1
206010061218 Inflammation Diseases 0.000 abstract 2
230000004054 inflammatory process Effects 0.000 abstract 2
239000013543 active substance Substances 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
201000008482 osteoarthritis Diseases 0.000 abstract 1
229960002739 oxaprozin Drugs 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Physical Education & Sports Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Steroid Compounds (AREA)
Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

ZA9704366A 1996-05-20 1997-05-20 Potassium, sodium and tris oxaprozin salt pharmaceutical formulations. ZA974366B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US1903396P	1996-05-20	1996-05-20

Publications (1)

Publication Number	Publication Date
ZA974366B true ZA974366B (en)	1998-05-20

Family

ID=21791076

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9704366A ZA974366B (en)	1996-05-20	1997-05-20	Potassium, sodium and tris oxaprozin salt pharmaceutical formulations.

Country Status (20)

Country	Link
US (1)	US6030643A (de)
EP (1)	EP0901372B1 (de)
JP (1)	JP4185974B2 (de)
KR (1)	KR20000015865A (de)
CN (1)	CN1129429C (de)
AT (1)	ATE299699T1 (de)
AU (1)	AU718030B2 (de)
BR (1)	BR9710448A (de)
CA (1)	CA2255064C (de)
CZ (1)	CZ370298A3 (de)
DE (1)	DE69733752T2 (de)
ES (1)	ES2248850T3 (de)
IL (1)	IL126998A (de)
NO (1)	NO985414L (de)
NZ (1)	NZ332861A (de)
PL (1)	PL330145A1 (de)
RU (1)	RU2197244C2 (de)
TW (1)	TW586929B (de)
WO (1)	WO1997044022A1 (de)
ZA (1)	ZA974366B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6596312B1 (en) *	1999-09-29	2003-07-22	R.P. Scherer Technologies, Inc.	Hydrolyzed cellulose granulations of salts of drugs
US6497157B1 (en) *	1999-11-29	2002-12-24	Distek, Inc.	Intrinsic dissolution apparatus with stationary sample holder
FR2828810B1 (fr) *	2001-08-27	2005-10-07	Lvmh Rech	Composition cosmetique a effet tenseur contenant un polymere d'origine naturelle et un agent hydratant polyhydroxyle
KR100574554B1 (ko) *	2004-05-28	2006-04-27	한미약품 주식회사	니아신의 경구투여용 서방성 조성물
US20060251689A1 (en) *	2005-03-30	2006-11-09	Astion Development A/S	Treatment or prevention of pruritus
AU2006228869A1 (en) *	2005-03-30	2006-10-05	Astion Pharma A/S	Oxaprozin or a closely related compound for the treatment of eczema
WO2006130726A2 (en) *	2005-06-01	2006-12-07	Teva Pharmaceutical Industries, Ltd.	Use of ladostigil for the treatment of multiple sclerosis
EP2124901B1 (de) *	2007-02-01	2017-07-19	Takeda Pharmaceutical Company Limited	Tablettenherstellung ohne verursachung von tablettierdefekten
TW201920110A (zh)	2009-01-16	2019-06-01	美商艾克塞里克斯公司	包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
TW201309650A (zh)	2011-02-10	2013-03-01	艾克塞里克斯公司	製造喹啉化合物之方法及包含該化合物之醫藥組合物
EP2854526B1 (de) *	2012-03-22	2018-04-25	vTv Therapeutics LLC	Tris(hydroxymethyl)aminomethan-salze eines kleinmolekularen glp1r-agonisten und pharmazeutische zusammensetzungen und verwendungen davon
EP3275433A1 (de)	2016-07-29	2018-01-31	Som Innovation Biotech S.L.	Zusammensetzung mit verzögerter freisetzung mit mikronisiertem tolcapon

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1206403A (en) *	1966-12-15	1970-09-23	Wyeth John & Brother Ltd	Oxazoles
US3578671A (en) *	1967-11-06	1971-05-11	Wyeth John & Brother Ltd	Oxazoles
US3998815A (en) *	1974-06-24	1976-12-21	Interx Research Corporation	1-hydrocarbonoyloxymethyl-3-carbamoyl or 3-carboethoxy-pyridinium salts
US4190584A (en) *	1976-08-13	1980-02-26	John Wyeth & Brother Limited	Process for preparing oxazoles
GB2097389B (en) *	1981-04-28	1984-11-28	Wyeth John & Brother Ltd	Oxazole derivative
IE52909B1 (en) *	1981-04-28	1988-04-13	Wyeth John & Brother Ltd	Oxazole derivatives
US4385049A (en) *	1981-05-12	1983-05-24	K-V Pharmaceutical Company	Stable high internal phase ratio topical emulsions
US4599359A (en) *	1982-12-09	1986-07-08	Stephen A. Cooper	Hydroxyzine-containing analgesic combinations
GB8329326D0 (en) *	1983-11-03	1983-12-07	Wyeth John & Brother Ltd	Oxazole derivatives
IT1204751B (it) *	1986-01-03	1989-03-10	Therapicon Srl	Derivati idrosolubili dell'acido 4,5 -difenil- 2 -ossazolpropionico,loro preparazione ed utilizzo in composizioni farmaceutiche
GB8630273D0 (en) *	1986-12-18	1987-01-28	Til Medical Ltd	Pharmaceutical delivery systems
US5059626A (en) *	1988-07-25	1991-10-22	Applied Analytical Industries, Inc.	Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
CA2058975C (en) *	1990-10-30	2000-06-06	Shuichi Kasai	Antiinflammatory gel preparation
WO1995007103A1 (en) *	1993-09-07	1995-03-16	The Procter & Gamble Company	Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
EP0717624A1 (de) *	1993-09-07	1996-06-26	The Procter & Gamble Company	Zusammensetzungen, welche aminosäure salzen von propionsäure nichtsteroiden antiinflammatorischen arzneimitteln und kaffein enthalten

1997
- 1997-05-14 AU AU30597/97A patent/AU718030B2/en not_active Ceased
- 1997-05-14 JP JP54242197A patent/JP4185974B2/ja not_active Expired - Fee Related
- 1997-05-14 CZ CZ983702A patent/CZ370298A3/cs unknown
- 1997-05-14 EP EP97925466A patent/EP0901372B1/de not_active Expired - Lifetime
- 1997-05-14 WO PCT/US1997/007637 patent/WO1997044022A1/en not_active Ceased
- 1997-05-14 BR BR9710448A patent/BR9710448A/pt not_active Application Discontinuation
- 1997-05-14 IL IL12699897A patent/IL126998A/xx not_active IP Right Cessation
- 1997-05-14 DE DE69733752T patent/DE69733752T2/de not_active Expired - Lifetime
- 1997-05-14 PL PL97330145A patent/PL330145A1/xx unknown
- 1997-05-14 NZ NZ332861A patent/NZ332861A/xx unknown
- 1997-05-14 ES ES97925466T patent/ES2248850T3/es not_active Expired - Lifetime
- 1997-05-14 CN CN97196583A patent/CN1129429C/zh not_active Expired - Fee Related
- 1997-05-14 KR KR1019980709415A patent/KR20000015865A/ko not_active Ceased
- 1997-05-14 CA CA002255064A patent/CA2255064C/en not_active Expired - Fee Related
- 1997-05-14 RU RU98123101/14A patent/RU2197244C2/ru not_active IP Right Cessation
- 1997-05-14 AT AT97925466T patent/ATE299699T1/de not_active IP Right Cessation
- 1997-05-16 US US08/857,999 patent/US6030643A/en not_active Expired - Fee Related
- 1997-05-20 ZA ZA9704366A patent/ZA974366B/xx unknown
- 1997-05-20 TW TW086106729A patent/TW586929B/zh not_active IP Right Cessation
1998
- 1998-11-20 NO NO985414A patent/NO985414L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
US6030643A (en)	2000-02-29
JP2001503734A (ja)	2001-03-21
PL330145A1 (en)	1999-04-26
KR20000015865A (ko)	2000-03-15
IL126998A (en)	2003-12-10
ES2248850T3 (es)	2006-03-16
BR9710448A (pt)	1999-08-17
NZ332861A (en)	2000-08-25
CA2255064A1 (en)	1997-11-27
AU3059797A (en)	1997-12-09
NO985414L (no)	1999-01-19
DE69733752T2 (de)	2006-06-01
TW586929B (en)	2004-05-11
CN1129429C (zh)	2003-12-03
EP0901372B1 (de)	2005-07-20
IL126998A0 (en)	1999-09-22
DE69733752D1 (de)	2005-08-25
AU718030B2 (en)	2000-04-06
CA2255064C (en)	2006-10-10
RU2197244C2 (ru)	2003-01-27
CN1225580A (zh)	1999-08-11
WO1997044022A1 (en)	1997-11-27
NO985414D0 (no)	1998-11-20
EP0901372A1 (de)	1999-03-17
JP4185974B2 (ja)	2008-11-26
CZ370298A3 (cs)	1999-05-12
ATE299699T1 (de)	2005-08-15

Publication	Publication Date	Title
EA199800772A1 (ru)	1999-04-29	Производные 6-фенилпиридил-2-амина
SG158733A1 (en)	2010-02-26	Cell adhesion inhibitors
SI0725779T1 (de)	2001-12-31
AU3368497A (en)	1998-01-07	Human dnase i hyperactive variants
ZA949309B (en)	1995-08-08	Composition for the production of therapeutic products in vivo
EA199700135A1 (ru)	1997-12-30	Ингибиторы клеточной адгезии
ZA943744B (en)	1995-04-26	Therapeutic substituted guanidines
HUT75555A (en)	1997-05-28	Lactobacillus strains of human origin, their compositions and uses thereof
BG104780A (en)	2001-10-31	Inhibitors of phospholipase enzymes
ZA98214B (en)	1999-08-11	Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
GB2288732B (en)	1998-04-29	Pharmaceutical compositions
AP2000001947A0 (en)	2000-12-31	Novel crystalline forms of an antiviral benzidazole compound.
IL110045A0 (en)	1994-10-07	Pharmaceutical compositions containing oligopeptides combating aids and arc and for immune stimulation and certain such novel oligopeptides
IL127918A0 (en)	1999-11-30	Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
IL126998A (en)	2003-12-10	Potassium, sodium or tris oxaprozin salt pharmaceutical formulations
BG102250A (en)	1999-02-26	The use of marigold-extracted glycosides for the treatment of psoriasis
MXPA94009086A (es)	2006-02-14	Guanidinas sustituidas terapeuticas.
EP1032556A4 (de)	2005-02-02	Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
NZ330944A (en)	2000-04-28	Peptide derivatives
GR3020355T3 (en)	1996-09-30	Aminosulfonyl urea acat inhibitors
PL316656A1 (en)	1997-02-03	Free halophantrin base for use in treating marsh-fever and compositions containing same
MX9403088A (es)	1997-02-28	Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
IL67940A0 (en)	1983-06-15	2,3-diaryl-5-halo-thiophenes,their preparation and pharmaceutical compositions containing them
AU6415994A (en)	1994-10-24	Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
GB9505082D0 (en)	1995-05-03	Medicament